Chronic kidney disease (CKD) affects more than 10% of the population worldwide and represents the second most important risk factor for preeclampsia, a life-threatening complication of pregnancy responsible for approximately 80,000 maternal and 500,000 perinatal deaths each year. Experimental studies have suggested a causal link between CKD, relative kynurenine deficiency during pregnancy, and preeclampsia development. Kynurenine, a tryptophan metabolite, plays a central role at the materno-fetal interface, supporting placental energy production, maternal-fetal immune tolerance, and placental perfusion. This study will prospectively assess and compare longitudinal kynurenine concentrations in pregnant women with and without CKD, and evaluate their associations with maternal and fetal outcomes.
Adult pregnant women <14 weeks of amenorrhea
With or without CKD stage 2-4 (eGFR 15-89 mL/min/1.73m², diagnosed before pregnancy)
Written informed consent
Affiliation to a social security system
Multiple pregnancy
Kidney transplantation
Persons under guardianship or legal protection
Single group
Blood sampling
Other interventionA 14ml blood sample will be collected during the first second and third trimesters of pregnancy and at 2 months (+ 1 month post partum)
Kynurenine concentration at the 3rd trimester (32±1 weeks) in women with and without CKD
Kynurenine concentrations at 1st, 2nd, 3rd trimesters and 2 months postpartum in women with and without CKD
preeclampsia
gestational hypertension
HELLP syndrome
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
